Titre : Réponse aux protéines mal repliées

Réponse aux protéines mal repliées : Questions médicales fréquentes

Termes MeSH sélectionnés :

Drug Development
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Réponse aux protéines mal repliées : Questions médicales les plus fréquentes", "headline": "Réponse aux protéines mal repliées : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Réponse aux protéines mal repliées : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-14", "dateModified": "2025-04-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Réponse aux protéines mal repliées" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Maturation post-traductionnelle des protéines", "url": "https://questionsmedicales.fr/mesh/D011499", "about": { "@type": "MedicalCondition", "name": "Maturation post-traductionnelle des protéines", "code": { "@type": "MedicalCode", "code": "D011499", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.308.670.600" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Dégradation associée au réticulum endoplasmique", "alternateName": "Endoplasmic Reticulum-Associated Degradation", "url": "https://questionsmedicales.fr/mesh/D060746", "about": { "@type": "MedicalCondition", "name": "Dégradation associée au réticulum endoplasmique", "code": { "@type": "MedicalCode", "code": "D060746", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.308.670.600.850.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Réponse aux protéines mal repliées", "alternateName": "Unfolded Protein Response", "code": { "@type": "MedicalCode", "code": "D056811", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Nektarios Barabutis", "url": "https://questionsmedicales.fr/author/Nektarios%20Barabutis", "affiliation": { "@type": "Organization", "name": "School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA, USA." } }, { "@type": "Person", "name": "Khadeja-Tul Kubra", "url": "https://questionsmedicales.fr/author/Khadeja-Tul%20Kubra", "affiliation": { "@type": "Organization", "name": "School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, USA." } }, { "@type": "Person", "name": "Federica Brandizzi", "url": "https://questionsmedicales.fr/author/Federica%20Brandizzi", "affiliation": { "@type": "Organization", "name": "MSU-DOE Plant Research Lab and Plant Biology Department Michigan State University, East Lansing, MI, USA. fb@msu.edu." } }, { "@type": "Person", "name": "Wensheng Lin", "url": "https://questionsmedicales.fr/author/Wensheng%20Lin", "affiliation": { "@type": "Organization", "name": "Department of Neuroscience; Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, USA." } }, { "@type": "Person", "name": "Mohammad S Akhter", "url": "https://questionsmedicales.fr/author/Mohammad%20S%20Akhter", "affiliation": { "@type": "Organization", "name": "School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Control of drug release from cotton fabric by nanofibrous mat.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35760164", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijbiomac.2022.06.138" } }, { "@type": "ScholarlyArticle", "name": "Foresee novel targets for Alzheimer's disease by investigating repurposed drugs.", "datePublished": "2022-06-22", "url": "https://questionsmedicales.fr/article/35733313", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2174/1871527321666220622162622" } }, { "@type": "ScholarlyArticle", "name": "Current emerging and investigational drugs for the treatment of chronic hand eczema.", "datePublished": "2022-06-17", "url": "https://questionsmedicales.fr/article/35658708", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/13543784.2022.2087059" } }, { "@type": "ScholarlyArticle", "name": "Burnout and Engagement's Relationship to Drug Abuse in Lawyers and Law Professionals.", "datePublished": "2022-06-16", "url": "https://questionsmedicales.fr/article/35732047", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/JOM.0000000000002550" } }, { "@type": "ScholarlyArticle", "name": "Diatomaceous earth as a drug-loaded carrier in a glass-ionomer cement.", "datePublished": "2022-06-15", "url": "https://questionsmedicales.fr/article/35738132", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jmbbm.2022.105324" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Régulation de l'expression des gènes", "item": "https://questionsmedicales.fr/mesh/D005786" }, { "@type": "ListItem", "position": 4, "name": "Modification traductionnelle des protéines", "item": "https://questionsmedicales.fr/mesh/D046188" }, { "@type": "ListItem", "position": 5, "name": "Maturation post-traductionnelle des protéines", "item": "https://questionsmedicales.fr/mesh/D011499" }, { "@type": "ListItem", "position": 6, "name": "Réponse aux protéines mal repliées", "item": "https://questionsmedicales.fr/mesh/D056811" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Réponse aux protéines mal repliées - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Réponse aux protéines mal repliées", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Réponse aux protéines mal repliées", "description": "Comment diagnostiquer une UPR ?\nQuels tests sont utilisés pour l'UPR ?\nL'imagerie est-elle utile pour l'UPR ?\nQuels biomarqueurs indiquent l'UPR ?\nL'historique médical aide-t-il au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D056811?mesh_terms=Drug+Development&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Réponse aux protéines mal repliées", "description": "Quels sont les symptômes de l'UPR ?\nL'UPR cause-t-elle des douleurs ?\nY a-t-il des symptômes neurologiques ?\nL'UPR affecte-t-elle le métabolisme ?\nDes symptômes digestifs sont-ils possibles ?", "url": "https://questionsmedicales.fr/mesh/D056811?mesh_terms=Drug+Development&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Réponse aux protéines mal repliées", "description": "Comment prévenir l'UPR ?\nL'évitement de toxines est-il important ?\nLes bilans de santé réguliers sont-ils utiles ?\nL'éducation sur l'UPR est-elle nécessaire ?\nLe soutien psychologique aide-t-il ?", "url": "https://questionsmedicales.fr/mesh/D056811?mesh_terms=Drug+Development&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Réponse aux protéines mal repliées", "description": "Quels traitements existent pour l'UPR ?\nL'alimentation influence-t-elle l'UPR ?\nLes exercices physiques sont-ils bénéfiques ?\nDes médicaments spécifiques sont-ils prescrits ?\nLa thérapie génique est-elle une option ?", "url": "https://questionsmedicales.fr/mesh/D056811?mesh_terms=Drug+Development&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Réponse aux protéines mal repliées", "description": "Quelles complications peuvent survenir ?\nL'UPR peut-elle entraîner des maladies chroniques ?\nY a-t-il un risque accru de cancer ?\nDes troubles cardiovasculaires sont-ils possibles ?\nL'UPR affecte-t-elle la longévité ?", "url": "https://questionsmedicales.fr/mesh/D056811?mesh_terms=Drug+Development&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Réponse aux protéines mal repliées", "description": "Quels sont les facteurs de risque de l'UPR ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il l'UPR ?\nLes maladies auto-immunes sont-elles un risque ?\nLe tabagisme est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D056811?mesh_terms=Drug+Development&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une UPR ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques et des marqueurs de stress cellulaire." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour l'UPR ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses de protéines et des biopsies tissulaires peuvent être effectuées." } }, { "@type": "Question", "name": "L'imagerie est-elle utile pour l'UPR ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications." } }, { "@type": "Question", "name": "Quels biomarqueurs indiquent l'UPR ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des protéines comme la CHOP et la GRP78 sont des biomarqueurs de l'UPR." } }, { "@type": "Question", "name": "L'historique médical aide-t-il au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'historique de maladies métaboliques ou génétiques est pertinent." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'UPR ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, douleurs musculaires et troubles métaboliques." } }, { "@type": "Question", "name": "L'UPR cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs musculaires et articulaires peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles cognitifs et des maux de tête peuvent être présents." } }, { "@type": "Question", "name": "L'UPR affecte-t-elle le métabolisme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des déséquilibres métaboliques et de la résistance à l'insuline." } }, { "@type": "Question", "name": "Des symptômes digestifs sont-ils possibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des nausées et des troubles gastro-intestinaux peuvent se manifester." } }, { "@type": "Question", "name": "Comment prévenir l'UPR ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un mode de vie sain et gérer le stress peut aider à prévenir l'UPR." } }, { "@type": "Question", "name": "L'évitement de toxines est-il important ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter les toxines environnementales peut réduire le risque d'UPR." } }, { "@type": "Question", "name": "Les bilans de santé réguliers sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des bilans réguliers peuvent détecter des problèmes précoces liés à l'UPR." } }, { "@type": "Question", "name": "L'éducation sur l'UPR est-elle nécessaire ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sensibiliser les patients et les professionnels est crucial pour la prévention." } }, { "@type": "Question", "name": "Le soutien psychologique aide-t-il ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le soutien psychologique peut réduire le stress et améliorer la santé globale." } }, { "@type": "Question", "name": "Quels traitements existent pour l'UPR ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies ciblées et des médicaments anti-inflammatoires." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle l'UPR ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut aider à réduire le stress cellulaire." } }, { "@type": "Question", "name": "Les exercices physiques sont-ils bénéfiques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice modéré peut améliorer la réponse au stress cellulaire." } }, { "@type": "Question", "name": "Des médicaments spécifiques sont-ils prescrits ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de la protéase peuvent être utilisés." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche pour corriger des défauts liés à l'UPR." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies métaboliques, des troubles neurologiques et des cancers peuvent survenir." } }, { "@type": "Question", "name": "L'UPR peut-elle entraîner des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'UPR est liée à des maladies chroniques comme le diabète et l'obésité." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'UPR est associée à un risque accru de certains types de cancer." } }, { "@type": "Question", "name": "Des troubles cardiovasculaires sont-ils possibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'UPR peut contribuer à des troubles cardiovasculaires et à l'inflammation." } }, { "@type": "Question", "name": "L'UPR affecte-t-elle la longévité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que l'UPR peut influencer la longévité et la santé globale." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de l'UPR ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le stress oxydatif, l'inflammation et des prédispositions génétiques." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement augmente le risque de dysfonctionnement de l'UPR." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il l'UPR ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent exacerber la réponse aux protéines mal repliées." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est lié à un stress cellulaire accru et à l'UPR." } } ] } ] }

Sources (10000 au total)

Foresee novel targets for Alzheimer's disease by investigating repurposed drugs.

Alzheimer's Disease (AD) is the most rampant neurodegenerative disorder which has caused havoc worldwide. More than a century has passed since the first case of AD was reported, but still no stable tr... Several drugs which were repurposed for AD were collected by following PRISMA 2020 systemic review. Databases like PubMed, ScienceDirect, JSTOR, and SciELO were used for data extraction. Further, Drug... Drugs like Zileuton, Salbutamol, Baricitinib, Carmustine, Paclitaxel, and Nilotinib were observed to be involved in regulation of neurotransmitters. Similarly, Metformin, Liraglutide, UDCA, and Bexaro... The study concluded that the reviewed drugs that follow similar biological and molecular processes can be repurposed for AD if chosen judiciously with current medications and thus drug repurposing is ...

Current emerging and investigational drugs for the treatment of chronic hand eczema.

Chronic hand eczema (CHE) is a highly prevalent, burdensome condition associated with functional impairment. Currently, topical therapeutics are the mainstay of CHE management. However, many cases are... Following a brief overview of CHE pathogenesis and existing treatments, this review will outline the mechanisms and available data on emerging and investigational drugs currently being studied in clin... Immunomodulatory drugs such as topical and systemic JAK inhibitors and Th2-targeting antibodies such as dupilumab are currently under investigation for CHE treatment, with early promise. Management of...

Burnout and Engagement's Relationship to Drug Abuse in Lawyers and Law Professionals.

Investigate the associations between drug abuse and the prevalence of the engagement and burnout dichotomy in law professionals.... Eligible participants completed a questionnaire where odds ratios of drug abuse and other confounding variables and their association to engagement or burnout were calculated using multiple logistic r... When looking at all law professionals, burnout is a statistically significant predictor for drug abuse ( P = 0.04, not shown). Law professionals whose burnout scores fell in the highest bin have 4.71 ... Study findings showed a possible way to affect the prevalence of drug abuse in law professionals by affecting the engagement and burnout dichotomy....

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents.

The last decade has seen development of numerous novel antipsychotic drugs with unique mechanisms including long-acting formulations for clinical use. A comparative assessment of these new drugs with ... Medline was searched from January 2010 to February 2022 for primary research articles and review articles in English using the search terms "extrapyramidal" and "tardive" with individual drug names of... We identified articles describing the risk of DIMD with 6 novel antipsychotics, 4 novel formulations, and 3 experimental antipsychotics. Both short- and long-term data generally showed comparable to l... Several novel antipsychotics, particularly lumateperone and pimavanserin, show promise in being able to treat psychosis while reducing the risk of DIMD. Long-acting paliperidone may reduce risk of DIM...

Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait.

Diabetes imposes a large burden on countries' healthcare expenditures. In Kuwait, diabetes prevalence in adults is estimated at 22.0%%-double the worldwide prevalence (9.3%). There is little current d... Estimate the utilization and cost of drugs for diabetes and diabetes-related complications and comorbidities in Kuwait for year 2018, as well determinants of costs.... This cross-sectional study used a multi-stage stratified sampling method. Patients were Kuwaiti citizens with diabetes, aged 18-80, recruited from all six governorates. Physicians collected demographi... Of 1182 diabetes patients, 64.0% had dyslipidemia and 57.7% had hypertension. Additionally, 40.7% had diabetes-related complications, most commonly neuropathy (19.7%). Of all diabetes patients, 85.9% ... Drug costs for treating diabetes and comorbidities/complications accounted for an estimated 22.8% of Kuwait's 2018 drug expenditures. Comorbidities and complications add 44.7% to the average drug cost...